Standard BioTools Announces Third Quarter Results for 2025

Financial Results Expectations

Standard BioTools Inc. (NASDAQ: LAB) announced that it will release its third quarter 2025 financial results on November 4, 2025, after the close of U.S. markets.

About the Company

Standard BioTools Inc. is a leading provider of solutions with a portfolio of standard and next-generation technologies that help biomedical researchers develop more effective drugs. SomaScan offers reliable insights into health and disease using mass cytometry and microfluidics technologies, transforming scientific discoveries into better patient outcomes. The company collaborates with leading academic institutions, government agencies, pharmaceutical and biotechnology companies, plant and animal research, and clinical laboratories worldwide, focusing on translational and clinical research in critical areas such as oncology, immunology, and immunotherapy.